James Condulis
Stock Analyst at Stifel
(2.09)
# 2,974
Out of 5,147 analysts
9
Total ratings
50%
Success rate
8.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $35.46 | +41.00% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $3.44 | +190.70% | 1 | Dec 5, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $24 | $12.49 | +92.15% | 1 | Sep 29, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $62.22 | +54.29% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $39.07 | +176.43% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $30.44 | -1.45% | 1 | Jan 22, 2025 |
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $35.46
Upside: +41.00%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $3.44
Upside: +190.70%
Aardvark Therapeutics
Sep 29, 2025
Initiates: Buy
Price Target: $24
Current: $12.49
Upside: +92.15%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $62.22
Upside: +54.29%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $39.07
Upside: +176.43%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $30.44
Upside: -1.45%